Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are ...

The present study was designed to evaluate the genetic mechanisms in patients with focal epileptiform discharges in the mid-temporal or central regions, an electroencephalographic abnormality of high ...

Researchers identify prochlorperazine as a potential new treatment for temporal lobe epilepsy by restoring the KCC2 chloride ...

Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, affecting a significant proportion of patients who develop drug-resistant epilepsy. Surgical interventions, particularly ...

An experimental neural cell therapy is safe and led to greater than 90% reduction in seizures in two patients with drug-resistant mesial temporal lobe epilepsy (MTLE) in the first-in-human test of the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted Regenerative Medicine Advanced Therapy designation to a novel regenerative cell therapy to ...

- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly ...

Many families face the challenge of drug-resistant epilepsy, questioning the transition from medication to surgery.